DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer

Technol Cancer Res Treat. 2023 Jan-Dec:22:15330338231167249. doi: 10.1177/15330338231167249.

Abstract

Objectives: DOT1L, a histone methylase, is overexpression in renal cell cancer. However, the role and detailed molecular mechanism of DOT1L involved in renal cancer development remain unknown.

Methods: The inhibition of DOT1L was used by SGC0946 and short hairpin RNA silencing. Monodansylcadaverine staining and transmission electron microscope were performed to detect autophagy changes as a result of the inhibition of DOT1L. MitoTracker Red assay was used to analyze mitochondrial morphology. The autophagy markers and mitochondria-related proteins were analyzed by Western blot, qPCR, or immunofluorescence. ChIP assay was performed to demonstrate H3K79me2 is involved in the direct regulation of Farnesoid X receptor transcription.

Results: DOT1L inhibition increased autophagy activity and promoted mito chondria fusion in cell lines of renal cancer. Inhibition of DOT1L upregulated levels of LC3α/β, P62, MFN1, and MFN2, which contributed to autophagy activity or mitochondria fusion. DOT1L knockdown showed a similar the above process. DOT1L inhibition or silencing resulted in AMP-activated protein kinase activation and mammalian target of rapamycin inhibition. Mechanistically, the DOT1L inhibitor and its short hairpin RNAs decreased the expression of Farnesoid X receptor in a histone methylase-dependent manner.

Conclusion: We revealed the essential role of Farnesoid X receptor in regulating DOT1L-induced autophagy and mitochondrial fission through the AMP-activated protein kinase/mammalian target of rapamycin pathway in cell lines of renal cancer, which may provide new insights into the pathogenesis of renal cell cancer.

Keywords: DOT1L; FXR; autophagy; mitochondria fusion; renal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Autophagy / genetics
  • Carcinoma, Renal Cell* / genetics
  • Cell Line
  • Histone Methyltransferases
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • Kidney Neoplasms* / genetics
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • Mitochondrial Dynamics / genetics
  • TOR Serine-Threonine Kinases

Substances

  • AMP-Activated Protein Kinases
  • Histone Methyltransferases
  • TOR Serine-Threonine Kinases
  • DOT1L protein, human
  • Histone-Lysine N-Methyltransferase